Literature DB >> 6818080

A prospective study of the effect of 12 months treatment on serum lipids and apolipoproteins A-I and B in Type 2 (non-insulin-dependent) diabetes.

K G Taylor, W G John, K A Matthews, A D Wright.   

Abstract

Serum high density lipoprotein cholesterol, total cholesterol, triglyceride and apolipoproteins A-I and B were studied at diagnosis and after 12 months conventional treatment in a group of Type 2 (non-insulin-dependent) diabetic patients. No significant deleterious effect on serum lipids and apolipoproteins was seen in any of the subgroups during the treatment period, although in the overall group there was a significant increase in serum total cholesterol in females. Serum high density lipoprotein cholesterol increased significantly in obese males treated with calorie restriction alone. There was a significant increase in serum apolipoprotein A-I in obese females treated with calorie restriction and metformin and in non-obese females treated with carbohydrate restriction and glibenclamide.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6818080     DOI: 10.1007/bf00254300

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  14 in total

1.  Relation of high-density lipoprotein cholesterol concentration to type of diabetes and its control.

Authors:  A L Kennedy; T R Lappin; T D Lavery; D R Hadden; J A Weaver; D A Montgomery
Journal:  Br Med J       Date:  1978-10-28

2.  Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study.

Authors:  M J Garcia; P M McNamara; T Gordon; W B Kannel
Journal:  Diabetes       Date:  1974-02       Impact factor: 9.461

3.  Atherosclerosis in diabetes mellitus. Correlations with serum lipid levels, adiposity, and serum insulin level.

Authors:  R J Santen; P W Willis; S S Fajans
Journal:  Arch Intern Med       Date:  1972-12

4.  Serum high-density lipoproteins in peripheral vascular disease.

Authors:  G V Bradby; A J Valente; K W Walton
Journal:  Lancet       Date:  1978-12-16       Impact factor: 79.321

5.  Rapid estimation (2 1/2 hours) of glycosylated haemoglobin for routine purposes.

Authors:  P A Kynoch; H Lehmann
Journal:  Lancet       Date:  1977-07-02       Impact factor: 79.321

6.  The continually changing 'natural history' of diabetes mellitus.

Authors:  M B Davidson
Journal:  J Chronic Dis       Date:  1981

7.  Evaluation of a new enzymatic kit for serum triglycerides.

Authors:  T Carter; P J Martin; P Wilding; D M Goldberg
Journal:  Clin Chem       Date:  1976-04       Impact factor: 8.327

8.  Factors contributing to deaths of diabetics under fifty years of age. On behalf of the Medical Services Study Group and British Diabetic Association.

Authors:  W M Tunbridge
Journal:  Lancet       Date:  1981-09-12       Impact factor: 79.321

9.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.

Authors:  T Gordon; W P Castelli; M C Hjortland; W B Kannel; T R Dawber
Journal:  Am J Med       Date:  1977-05       Impact factor: 4.965

10.  Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions.

Authors:  M Burstein; H R Scholnick; R Morfin
Journal:  J Lipid Res       Date:  1970-11       Impact factor: 5.922

View more
  9 in total

Review 1.  [Value of biguanide in therapy of diabetes mellitus].

Authors:  E Haupt; U Panten
Journal:  Med Klin (Munich)       Date:  1997-08-15

Review 2.  Treatment of diabetes: the effect on serum lipids and lipoproteins.

Authors:  P K Merrin; R S Elkeles
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

Review 3.  A risk-benefit assessment of metformin in type 2 diabetes mellitus.

Authors:  H C Howlett; C J Bailey
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

Review 4.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 5.  Adverse cardiovascular effects of sulphonylurea drugs. Clinical significance.

Authors:  R Huupponen
Journal:  Med Toxicol       Date:  1987 May-Jun

6.  Glycosylated Haemoglobin (HbA1c) - A Marker of Circulating Lipids in Type 2 Diabetic Patients.

Authors:  Prabhavathi K; Kirthana Kunikullaya U; Jaisri Goturu
Journal:  J Clin Diagn Res       Date:  2014-02-03

7.  Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles.

Authors:  L S Hermann; J E Karlsson; A Sjöstrand
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 8.  Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use.

Authors:  A Melander; P O Bitzén; O Faber; L Groop
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

9.  Effects of Glimepiride vs Glibenclamide on Ischaemic Heart Disease Risk Factors and Glycaemic Control in Patients with Type 2 Diabetes Mellitus.

Authors:  M E Britton; A E Denver; V Mohamed-Ali; J S Yudkin
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 3.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.